vs
Side-by-side financial comparison of T Stamp Inc (IDAI) and China SXT Pharmaceuticals, Inc. (SXTC). Click either name above to swap in a different company.
T Stamp Inc is the larger business by last-quarter revenue ($908.9K vs $829.5K, roughly 1.1× China SXT Pharmaceuticals, Inc.). China SXT Pharmaceuticals, Inc. runs the higher net margin — -96.8% vs -279.9%, a 183.1% gap on every dollar of revenue. On growth, China SXT Pharmaceuticals, Inc. posted the faster year-over-year revenue change (0.0% vs -39.3%). T Stamp Inc produced more free cash flow last quarter ($2.0M vs $-1.8M).
T Stamp Inc, trading under ticker IDAI, develops AI-powered identity verification, trust scoring, and fraud prevention solutions. It serves clients across fintech, healthcare, and e-commerce segments, primarily operating in North America to help organizations securely authenticate user identities and mitigate fraud risks.
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the Chinese domestic market. It engages in the research, development, production and distribution of traditional Chinese medicine-based prescription drugs, over-the-counter medications, and nutritional health products, serving both clinical medical institutions and consumer health markets.
IDAI vs SXTC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $908.9K | $829.5K |
| Net Profit | $-2.5M | $-802.6K |
| Gross Margin | — | 16.2% |
| Operating Margin | -224.9% | -76.9% |
| Net Margin | -279.9% | -96.8% |
| Revenue YoY | -39.3% | 0.0% |
| Net Profit YoY | 57.7% | 0.0% |
| EPS (diluted) | $-0.37 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $908.9K | — | ||
| Q3 25 | $872.5K | $829.5K | ||
| Q2 25 | $812.7K | — | ||
| Q1 25 | $545.5K | — | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | $511.1K | $829.5K | ||
| Q2 24 | $500.4K | — | ||
| Q1 24 | $573.7K | — |
| Q4 25 | $-2.5M | — | ||
| Q3 25 | $-1.9M | $-802.6K | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-2.2M | — | ||
| Q4 24 | $-6.0M | — | ||
| Q3 24 | $-1.3M | $-802.6K | ||
| Q2 24 | $-2.6M | — | ||
| Q1 24 | $-2.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 16.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -224.9% | — | ||
| Q3 25 | -203.0% | -76.9% | ||
| Q2 25 | -207.0% | — | ||
| Q1 25 | -396.5% | — | ||
| Q4 24 | -81.2% | — | ||
| Q3 24 | -523.7% | -76.9% | ||
| Q2 24 | -524.7% | — | ||
| Q1 24 | -496.7% | — |
| Q4 25 | -279.9% | — | ||
| Q3 25 | -219.1% | -96.8% | ||
| Q2 25 | -210.7% | — | ||
| Q1 25 | -395.5% | — | ||
| Q4 24 | -401.5% | — | ||
| Q3 24 | -245.7% | -96.8% | ||
| Q2 24 | -519.3% | — | ||
| Q1 24 | -466.9% | — |
| Q4 25 | $-0.37 | — | ||
| Q3 25 | $-0.72 | — | ||
| Q2 25 | $-0.69 | — | ||
| Q1 25 | $-0.89 | — | ||
| Q4 24 | $-3.14 | — | ||
| Q3 24 | $-1.06 | $-0.25 | ||
| Q2 24 | $-3.19 | — | ||
| Q1 24 | $-3.97 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.0M | $18.1M |
| Total DebtLower is stronger | — | $105.0K |
| Stockholders' EquityBook value | $8.7M | $15.4M |
| Total Assets | $11.2M | $21.7M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.0M | — | ||
| Q3 25 | $5.4M | $18.1M | ||
| Q2 25 | $292.1K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $598.0K | $18.5M | ||
| Q2 24 | $659.5K | — | ||
| Q1 24 | $816.7K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $105.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $952.3K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $8.7M | — | ||
| Q3 25 | $6.1M | $15.4M | ||
| Q2 25 | $2.4M | — | ||
| Q1 25 | $4.1M | — | ||
| Q4 24 | $3.0M | — | ||
| Q3 24 | $5.4M | $15.0M | ||
| Q2 24 | $750.4K | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | $11.2M | — | ||
| Q3 25 | $11.2M | $21.7M | ||
| Q2 25 | $5.7M | — | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $8.6M | — | ||
| Q3 24 | $10.6M | $31.0M | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $5.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-1.4M |
| Free Cash FlowOCF − Capex | $2.0M | $-1.8M |
| FCF MarginFCF / Revenue | 215.4% | -216.2% |
| Capex IntensityCapex / Revenue | 0.8% | 4.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-5.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-4.0M | $-1.4M | ||
| Q2 25 | $-2.1M | — | ||
| Q1 25 | $-1.5M | — | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-2.4M | $-1.4M | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-2.2M | — |
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-4.0M | $-1.8M | ||
| Q2 25 | $-2.1M | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-2.2M | — |
| Q4 25 | 215.4% | — | ||
| Q3 25 | -459.6% | -216.2% | ||
| Q2 25 | -258.6% | — | ||
| Q1 25 | -289.2% | — | ||
| Q4 24 | -182.9% | — | ||
| Q3 24 | -475.4% | — | ||
| Q2 24 | -320.9% | — | ||
| Q1 24 | -376.6% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.0% | 4.9% | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 0.5% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
